The Myeloma Beacon The guidelines recommend that multiple myeloma patients who are receiving Revlimid (lenalidomide) or thalidomide (Thalomid) with chemotherapy or dexamethasone (Decadron) should receive medication to prevent blood clots. Specifically, those who are ...
Zacks.com The drug is also approved in many countries across the globe in combination with dexamethasone for treating multiple myeloma patients, who have been treated at least once for the disease. Approval in the EU for the MDS indication would further boost ...
MarketWatch Bristol-Myers Squibb Company (NYSE:BMY) and AbbVie (NYSE:ABBV) today announced updated efficacy and safety data from a small, randomized Phase 2, open-label study in patients with previously-treated multiple myeloma that evaluated two doses of ...
PharmiWeb.com (press release) ACY-100 is a single arm multicenter open label Phase 1/2 study with dose escalation of ACY-1215 as a monotherapy and in combination with Velcade¬Æ (bortezomib Takeda Millennium) and dexamethasone for the treatment of patients with relapsed or ... and more »
PharmaTimes Indeed, at EHA, updated results were presented on Celgene's follow-up to Revlimid, pomalidomide, from the MM-003 study that compares the drug in combination ...
